SBIR/STTR Research Award

NOVEL ANTI-QUORUM SENSING AGENT

Award identifier ea58b068c14807f7061b6f166494de521a4f8f582b294ad2a66179caab3b8b17Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Panorama Research Incorporated
Proposal award date
Not reported
Contract end date
Not reported
UEI
LYVHC3ARFRJ7
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Provided by applicant): The opportunistic human pathogen P. aeruginosa utilizes N-acylhomoserine lactones as quorum sensing "autoinducers" to specifically induce numerous virulence genes. AiiA is the first enzyme known to inactivate N-acylhomoserine lactones. Expression of AiiA in transformed Erwinia carotovora strain SCG1 significantly reduces the release of AI, decreases extracellular pectolytic enzyme activities, and attenuates pathogenicity on potato, eggplant, Chinese cabbage, carrot, celery, cauliflower, and tobacco. Plants transgenic for AiiA are resistant to E. carotovora infection (Dong et al., 2001). Based on these proof-of-principle studies we shall link this enzyme to a human antibody heavy chain to create a stabilized molecule suitable for human use. In phase I we will make a chimaeric AiiA-Ig by fusing the cDNA of AiiA to the N terminus of the CHI of human IgG1. AiiA-Ig will be expressed in mammalian cells and the protein purified by affinity chromatography. Finally we will demonstrate the capacity of AiiA-Ig to attenuate P. aeruginosa virulence factor expression in vitro. In phase II we will demonstrate activity of AiiA-Ig to attenuate pathogenesis of P. aeruginosa infection in mouse models (eg. lung, sepsis, burn), prepare a deimmunized or PEG-linked form of AiiA-Ig suitable for human therapeutic use and begin to carry out preclinical pharmacology and toxicology studies with the lead molecule. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

149 SBIR/STTR records share this UEI (1990–2025). Reported award amounts total $35,373,004. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Agriculture, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.